

October 29, 2025



## **LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3**

**BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE)** -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT, LIXTW), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today announced that Geordan Pursglove, its chief executive officer, will present at the *Spartan Capital Investor Conference 2025* in New York, on November 3, 2025, at 4 p.m. ET. Management will conduct one-on-one meetings with investors during the conference.

The conference will be held at the Marriott Marquis Hotel, 1535 Broadway. To register or schedule a one-on-one meeting, please visit <https://spartancapital.com/spartan-capital-investor-conference-2025/>.

### **About LIXTE Biotechnology Holdings, Inc.**

[LIXTE Biotechnology Holdings, Inc.](https://www.liخته.com) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see [www.liخته.com](https://www.liخته.com)), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.

LIXTE's lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information about LIXTE can be found at [www.liخته.com](https://www.liخته.com).

### **For more information about LIXTE, contact:**

[info@liخته.com](mailto:info@liخته.com)

General Phone: (631) 830-7092; Investor Phone: (888) 289-5533

or

PondelWilkinson Inc. Investor Relations [pwinvestor@pondel.com](mailto:pwinvestor@pondel.com)

Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962



Source: Lixte Biotechnology Holdings, Inc.